Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
131I-AuNPs@PEG-SP94 is a preclinical radiolabeled gold nanoparticle conjugate designed for the targeted treatment of liver cancer (hepatocellular carcinoma). The therapeutic agent consists of gold nanoparticles (AuNPs) modified with thiol-polyethylene glycol (HS-PEG-COOH) and conjugated to the SP94 peptide, which specifically targets glucose-regulated protein 78 (GRP78) overexpressed on the surface of liver cancer cells. The nanoparticles are radiolabeled with iodine-131 (131I) using the chloramine T method. Upon binding to GRP78, the conjugate is internalized, delivering localized beta and gamma radiation from the 131I isotope to induce DNA damage, reactive oxygen species (ROS) accumulation, and apoptosis in tumor cells, while promoting immunogenic cell death.
| Indication | Highest phase | Status |
|---|---|---|
| hepatocellular carcinoma (HCC) | Preclinical | Active |
Every indication, with countries and timelines, is in the full profile.
| Market | Status | Year |
|---|---|---|
| United States | Not approved | — |
| European Union | Not approved | — |
| China | Not approved | — |
| Japan | Not approved | — |
Approved indications and other markets are in the full profile.
Lead indication: hepatocellular carcinoma (HCC)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 131I-AuNPs@PEG-SP94.
Work on 131I-AuNPs@PEG-SP94? Claim this page to correct or add information. Claim this page